Comparative analysis of various tumor‐associated antigen‐specific t‐cell responses in patients with hepatocellular carcinoma

Many tumor‐associated antigens (TAAs) recognized by cytotoxic T cells (CTLs) have been identified during the last two decades and some of them have been used in clinical trials. However, there are very few in the field of immunotherapy for hepatocellular carcinoma (HCC) because there have not been comparative data regarding CTL responses to various TAAs. In the present study, using 27 peptides derived from 14 different TAAs, we performed comparative analysis of various TAA‐specific T‐cell responses in 31 HCC patients to select useful antigens for immunotherapy and examined the factors that affect the immune responses to determine a strategy for more effective therapy. Twenty‐four of 31 (77.4%) HCC patients showed positive responses to at least one TAA‐derived peptide in enzyme‐linked immunospot assay. The TAAs consisting of cyclophilin B, squamous cell carcinoma antigen recognized by T cells (SART) 2, SART3, p53, multidrug resistance‐associated protein (MRP) 3, alpha‐fetoprotein (AFP) and human telomerase reverse transcriptase (hTERT) were frequently recognized by T cells and these TAA‐derived peptides were capable of generating peptide‐specific CTLs in HCC patients, which suggested that these TAAs are immunogenic. HCC treatments enhanced TAA‐specific immune responses with an increased number of memory T cells and induced de novo T‐cell responses to lymphocyte‐specific protein tyrosine kinase, human epidermal growth factor receptor type 2, p53, and hTERT. Blocking cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) resulted in unmasking of TAA‐specific immune responses by changing cytokine and chemokine profiles of peripheral blood mononuclear cells stimulated by TAA‐derived peptides. Conclusion: Cyclophilin B, SART2, SART3, p53, MRP3, AFP, and hTERT were immunogenic targets for HCC immunotherapy. TAA‐specific immunotherapy combined with HCC treatments and anti‐CTLA‐4 antibody has the possibility to produce stronger tumor‐specific immune responses. (HEPATOLOGY 2011;)

[1]  K. Kurokohchi,et al.  A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection. , 2001, Journal of hepatology.

[2]  Y. Horiguchi,et al.  Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  K. Itoh,et al.  A newly identified MAGE‐3‐derived epitope recognized by HLA‐A24‐restricted cytotoxic T lymphocytes , 1999, International journal of cancer.

[4]  M. Kojiro,et al.  Immunohistologic study on the expressions of α‐fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma , 2001, Hepatology.

[5]  T. Tsurumi,et al.  Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. , 2001, Blood.

[6]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[7]  A. Ribas,et al.  A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  H. Yamana,et al.  Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases , 2001, European journal of immunology.

[9]  E. Appella,et al.  A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  日本肝癌研究会.  Classification of primary liver cancer , 1997 .

[11]  S. Furui,et al.  Dynamic CT densitometry of hepatic tumors. , 1980, AJR. American journal of roentgenology.

[12]  H. Tanaka,et al.  Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53 , 2001, British Journal of Cancer.

[13]  H. Tanaka,et al.  Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas , 2001, British Journal of Cancer.

[14]  A. Bertoletti,et al.  Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. , 2009, Gastroenterology.

[15]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[16]  M. Nakao,et al.  A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. , 1999, Journal of immunology.

[17]  H. Fujita,et al.  Identification of a Gene Coding for a New Squamous Cell Carcinoma Antigen Recognized by the CTL1 , 2000, The Journal of Immunology.

[18]  H. Pehamberger,et al.  Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  L. Butterfield.  Recent advances in immunotherapy for hepatocellular cancer. , 2006, Swiss medical weekly.

[20]  R. Kennedy,et al.  Multiple roles for CD4+ T cells in anti‐tumor immune responses , 2008, Immunological reviews.

[21]  Akira Yamada,et al.  Personalized peptide vaccines: A new therapeutic modality for cancer , 2006, Cancer science.

[22]  S. Shichijo,et al.  A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. , 2000, Cancer research.

[23]  A. Ribas,et al.  T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  R. Lencioni,et al.  Local-regional treatment of hepatocellular carcinoma. , 2012, Radiology.

[25]  G. Missale,et al.  Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. , 2006, Cancer research.

[26]  P. Badrinath,et al.  Trends in primary liver cancer , 1998, The Lancet.

[27]  E. L. Calhoon.  Immune therapy of cancer. , 1988, The Journal of the Oklahoma State Medical Association.

[28]  Zheng Zhang,et al.  Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. , 2007, Gastroenterology.

[29]  K. Shirouzu,et al.  Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. , 1999, Cancer research.

[30]  Antoni Ribas,et al.  Current developments in cancer vaccines and cellular immunotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  K. Itoh,et al.  Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. , 2001, Cancer research.

[32]  A. Ribas,et al.  A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides , 2006, Clinical Cancer Research.

[33]  H. Yamana,et al.  Identification of a SART‐1‐derived peptide capable of inducing HLA‐A24‐restricted and tumor‐specific cytotoxic T lymphocytes , 1999, International journal of cancer.

[34]  S. Kaneko,et al.  Identification of α‐fetoprotein‐derived peptides recognized by cytotoxic T lymphocytes in HLA‐A24+ patients with hepatocellular carcinoma , 2006 .

[35]  F. Tanaka,et al.  A MAGE‐1‐encoded HLA‐A24‐binding synthetic peptide induces specific anti‐tumor cytotoxic T lymphocytes , 1999, International journal of cancer.

[36]  G. Missale,et al.  Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. , 2004, Journal of hepatology.

[37]  S. Oka,et al.  Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. , 1997, Journal of immunology.

[38]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[39]  C. Harris,et al.  TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer , 2007, Oncogene.

[40]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[41]  S. Kaneko,et al.  Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma , 2006, Hepatology.

[42]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[43]  A. Burroughs,et al.  Unmasking of α-Fetoprotein-Specific CD4+ T Cell Responses in Hepatocellular Carcinoma Patients Undergoing Embolization1 , 2007, The Journal of Immunology.

[44]  K. Saigenji,et al.  Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: Risk factors and patterns , 2008, Journal of Gastroenterology.

[45]  S. Kaneko,et al.  Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. , 2006, International journal of cancer.

[46]  A. Hagnéré,et al.  Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer. , 2001, Human immunology.

[47]  S. Quezada,et al.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies , 2009, The Journal of experimental medicine.

[48]  R. Lencioni.  Loco‐regional treatment of hepatocellular carcinoma , 2010, Hepatology.

[49]  K. Tanaka,et al.  Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. , 2000, Cancer research.